Natera (NTRA)
NASDAQ:NTRA
NTRA Stock Chart & Stats
$196.15
$1.33(0.78%)
At close: 4:00 PM EST
$196.15
$1.33(0.78%)
Day’s Range― - ―
52-Week Range$125.38 - $256.36
Previous CloseN/A
Volume352.74K
Average Volume (3M)1.18M
Market Cap
$27.80B
Enterprise Value$26.94B
Total Cash (Recent Filing)$1.08B
Total Debt (Recent Filing)$214.38M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
May 07, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.36
Shares Outstanding141,731,250
10 Day Avg. Volume1,373,040
30 Day Avg. Volume1,177,884
Financial Highlights & Ratios
PEG Ratio230.22
Price to Book (P/B)18.29
Price to Sales (P/S)13.58
P/FCF Ratio287.05
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue11.68
Enterprise Value/Gross Profit18.01
Enterprise Value/Ebitda-104.47
Forecast
1Y Price Target
$262.57Price Target Upside33.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-1.81
Revenue Forecast (FY)$2.67B
Bulls Say, Bears Say
Bulls Say
Operating Leverage And GuidanceManagement's revenue guidance and the expectation that revenue growth will outpace operating expenses support improving operating leverage and expanding margins.
Product AdoptionRecord growth in Signatera test volumes and improving pricing per test indicate broad clinician adoption and accelerating oncology revenue momentum.
Product Pipeline And InnovationExpanded research and development investment combined with upcoming test launches and planned artificial intelligence lab efficiencies create multiple pathways to higher revenue and lower per-test costs.
Bears Say
Competition And Clinical Evidence DependencyWider adoption depends on practice‑changing outcomes studies and defending position against growing competitors, which makes near-term upside contingent on clinical evidence and competitive dynamics.
Reimbursement UncertaintyA meaningful share of Signatera tests remains unreimbursed, leaving revenue exposed to delays in payer coverage expansion and reimbursement decisions.
Valuation RiskA rich market valuation assumes continued outperformance and guidance upgrades, increasing downside risk if future results fall short of elevated expectations.
Natera News
NTRA FAQ
What was Natera’s price range in the past 12 months?
Natera lowest stock price was $125.38 and its highest was $256.36 in the past 12 months.
What is Natera’s market cap?
Natera’s market cap is $27.80B.
When is Natera’s upcoming earnings report date?
Natera’s upcoming earnings report date is May 07, 2026 which is in 41 days.
How were Natera’s earnings last quarter?
Natera released its earnings results on Feb 26, 2026. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of -$0.512 by $0.872.
Is Natera overvalued?
According to Wall Street analysts Natera’s price is currently Undervalued.
Does Natera pay dividends?
Natera does not currently pay dividends.
What is Natera’s EPS estimate?
Natera’s EPS estimate is -0.54.
How many shares outstanding does Natera have?
Natera has 141,731,250 shares outstanding.
What happened to Natera’s price movement after its last earnings report?
Natera reported an EPS of $0.36 in its last earnings report, beating expectations of -$0.512. Following the earnings report the stock price went down -3.73%.
Which hedge fund is a major shareholder of Natera?
Currently, no hedge funds are holding shares in NTRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Natera Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$262.57 (33.86% Upside)
$262.57 (33.86% Upside)
Blogger Sentiment
Bullish
NTRA Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 804.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.68%
12-Months-Change
Fundamentals
Return on Equity
-15.28%
Trailing 12-Months
Asset Growth
48.72%
Trailing 12-Months
Company Description
Natera
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
NTRA Company Deck
NTRA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong set of operational and financial achievements: record testing volumes, robust 40% YoY revenue growth, materially improved gross margins (66.9% reported; 63.7% organic), improved collections (DSO down to 47 days), >$107M cash flow for 2025, and a clear product and clinical momentum (Signatera, Latitude submission, phased variants, Fetal Focus, Prospera trials). Management provided confident 2026 guidance (revenue $2.62B–$2.7B; gross margin 63%–65%) while acknowledging a few nonrecurring Q4 tailwinds and the ongoing dependency on reimbursement expansion for further ASP/margin upside. Risks called out include one-time accounting benefits, potential non-repeatability of some Q4 drivers, and the need for broader MolDX/Medicare coverage for a subset of indications. Overall, the positives (strong growth, margin expansion, cash generation, major product/technology advances and clinical evidence) substantially outweigh the identified risks and caveats.View all NTRA earnings summariesNTRA Stock 12 Month Forecast
Average Price Target
$262.57
▲(33.86% Upside)
Technical Analysis
Ownership Overview
4.40% Insiders
34.02% Mutual Funds
26.72% Other Institutional Investors
19.57% Public Companies and
Individual Investors